Circulating microRNA Profiles in Patients with Type-1 Autoimmune Hepatitis

Kiyoshi Migita1*, Atsumasa Komori1, Hideko Kozuru1, Yuka Jiuchi1, Minoru Nakamura2, Michio Yasunami3, Hiroshi Furukawa4, Seigo Abiru1, Kazumi Yamasaki1, Shinya Nagaoka1, Satoru Hashimoto1, Shigemune Bekki1, Hiroshi Kamitsukasa1, Yoko Nakamura1, Hajime Ohta1, Masaaki Shimada1, Hironao Takahashi1, Eiji Mita1, Taizo Hijioka1, Haruhiro Yamashita1, Hiroshi Kouno1, Makoto Nakamuta1, Keisuke Ario1, Toyokichi Muro1, Hironori Sakai1, Kazuhiro Sugii1, Hideo Nishimura1, Kaname Yoshizawa1, Takeaki Sato1, Atsushi Naganuma1, Tatsuji Komatsu1, Yukio Oohara1, Fujio Makita1, Minoru Tomizawa1, Hiroshi Yatsuhashi1

1 NHO-AIH study group, Nagasaki Medical Center, kubara 2-1001-1 Omura, Nagasaki, 856–8562, Japan,
2 Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, Japan,
3 Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Sakamoto 1-7-1, Nagasaki, 852–8501, Japan,
4 Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305–8575, Japan

* migita@nagasaki-mc.com

Abstract

Recent studies have demonstrated that micro (mi)RNA molecules can be detected in the circulation and can serve as potential biomarkers of various diseases. This study used microarray analysis to identify aberrantly expressed circulating miRNAs in patients with type 1 autoimmune hepatitis (AIH) compared with healthy controls. Patients with well-documented and untreated AIH were selected from the National Hospital Organization (NHO)-AIH-liver-network database. They underwent blood sampling and liver biopsy with inflammation grading and fibrosis staging before receiving treatment. To further confirm the microarray data, circulating expression levels of miR-21 and miR-122 were quantified by real-time quantitative polymerase chain reaction in 46 AIH patients, 40 patients with chronic hepatitis C (CHC), and 13 healthy controls. Consistent with the microarray data, serum levels of miR-21 were significantly elevated in AIH patients compared with CHC patients and healthy controls. miR-21 and miR-122 serum levels correlated with alanine aminotransferase levels. Circulating levels of miR-21 and miR-122 were significantly reduced in AIH patients with liver cirrhosis, and were inversely correlated with increased stages of fibrosis. By contrast, levels of circulating miR-21 showed a significant correlation with the histological grades of inflammation in AIH. We postulate that aberrantly expressed serum miRNAs are potential biomarkers of AIH and could be implicated in AIH pathogenesis. Alternations of miR-21 and miR-122 serum levels could reflect their putative roles in the mediation of inflammatory processes in AIH.
Introduction

Micro RNAs (miRNAs) are small endogenous RNA molecules of 19–24 nucleotides that control the translation and transcription of targeting RNAs by base-pairing to complementary sites [1]. Serum miRNA expression is stable, reproducible, and consistent among individuals of the same species, and specific expression patterns have been identified as biomarkers for numerous diseases and cancers [2]. For example, miR-122, the most abundant miRNA in hepatocytes, has a well-defined role in hepatitis C virus (HCV) replication, and serves as a viable therapeutic target [3]. A role for miR-122 is also emerging in other liver diseases [4].

Ample evidence exists for the important regulatory potential of other miRNAs in conditions associated with liver inflammation, the metabolic syndrome, or autoimmune processes [5]. miRNAs regulate the function of both the innate and the adaptive immune system, and altered miRNA expression has been reported in human autoimmune diseases [6]. For instance, a unique miRNA expression profile was demonstrated in the sera from an individual with the autoimmune liver disease primary biliary cirrhosis [7].

Autoimmune hepatitis (AIH) is a rare disease characterized by hypergammaglobulinemia, the production of autoantibodies and a good response to immunosuppression [8]. Different subtypes of AIH may be distinguished from differences in the autoantibody patterns. For example, AIH type 1 is characterized by anti-nuclear antibodies (ANA) and/or anti-smooth muscular antibodies (SMA) [9]. The etiology of AIH is unknown, but it is thought to have both a genetic and an environmental basis [10]. miRNAs are emerging as highly tissue-specific biomarkers with the potential applicability to revolutionize disease diagnosis and treatment [11]. In this study, therefore, we used microarray for the initial screening followed by quantitative reverse transcription PCR (qRT-PCR) validation to analyze serum samples from patients with type I AIH. Our results demonstrated that the unique expression pattern of serum miRNAs can serve as a non-invasive biomarker for AIH.

Materials and Methods

Study population

Patients with well-documented and untreated AIH were enrolled from the National Hospital Organization (NHO)-AIH-liver-network database, a multicenter registry for Japanese patients with AIH [12]. Almost patients were enrolled in Nagasaki Medical Center and Nagoya Medical Center. All patients satisfied the 1999 revised criteria of International Autoimmune Hepatitis Group diagnosis of type-1 AIH [13]. Patients were excluded from the study if there was histological evidence of cholangitis or non-alcoholic steatohepatitis. Patients positive for hepatitis B virus surface antigen or HCV RNA were also excluded. Patients with other causes of liver disease, such as excess alcohol or drug use, were excluded based on reviews of their appropriate history and investigations. As controls, patients with chronic hepatitis C (CHC) (n = 40; female/male = 20/20; genotype 1b:29, 2a:7, 2b:4; mean age, 60.5±9.3 years; aspartate aminotransferase (AST), 76.0±63.0 IU/L; alanine transaminase (ALT), 94.5±96.8 IU/L), and healthy controls (n = 13; female/male = 7/6; mean age, 42.5±14.4 years) were included. The study was approved by the Ethics Committee of the NHO Central Internal Review Board and participating NHO liver-network hospitals. Written informed consent was obtained from each individual.

Clinical and histological assessments

Serum concentrations of type IV collagen were determined with a commercial RIA kit (Panasay IV. C, Daiichi Chemical Co. Ltd. Tokyo, Japan).
Liver biopsy and laboratory tests were obtained at baseline prior to treatment. In the histological diagnosis of AIH, each specimen was assessed for inflammatory grading including the degree of portal inflammation, presence of interface hepatitis, and the degree of parenchymal inflammation, as well as the stage of fibrosis (0, absent; 1, expansion of fibrosis to parenchyma; 2, portal–central or portal–portal bridging fibrosis; 3, presence of numerous fibrous septa; and 4, multi-nodular cirrhosis) according to the criteria of Desmet et al. [14]. Cirrhosis was diagnosed histologically when a loss of normal lobular architecture, reconstruction of hepatic nodules, and the presence of regenerative nodules were observed.

**Microarray analysis of serum miRNAs**

We prepared a serum pool from five patients with untreated with acute-onset type AIH and stocked paired sera before/after glucocorticoid treatments. A control miRNA pool from five healthy subjects. RNA was isolated from serum samples using QIAzol reagent according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Microarray analysis was performed to evaluate miRNA expression patterns in serum pools from patients and controls using 3D-Gene miRNA Oligo chips according to the manufacturer’s instructions (Toray Industries, Inc., Tokyo, Japan). Small RNAs from serum were labelled using the miRCURY LNA microRNA Array Power Labelling Kit (Exiqon, Palm Beach FL, USA) and analyzed using 3D-Gene miRNA Oligo chips Ver. 17.0 (Toray Industries Inc.) containing more than 1700 antisense probes printed in duplicate spots, according to the manufacturer’s instructions. Signals were analyzed using the 3D-Gene Scanner 3000 (Toray Industries Inc. Tokyo, Japan). microRNAs array data from this study are in agreement with the Minimum Information About a Microarray Experiment (MIAME) and are publicly available through the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/projects/geo/) under the accession number GSE71432.

**Quantitative reverse transcription PCR validation study**

More serum samples of AIH patients (n = 46), CHC patients (n = 40), and healthy controls (n = 13) were used in a qRT-PCR validation study. We followed the protocol previously reported by Mitchell et al. [15] to determine endogenous levels of *Caenorhabditis elegans* miR-39 miRNA (miRNeasy Serum/plasma Spike-In Control). RNA was isolated from serum samples using Qiazol reagent according to the manufacturer’s instructions (Qiagen, Limburg, the Netherlands). *C. elegans* miR-39 (Qiagen) was added to serum samples (1.6 ×10^8 copies/μl) prior to the RNA isolation procedure for the later normalization of extracellular miR-122 and miR-21 levels. The RNA quality was assessed by microcapillary electrophoresis (2100 BioAnalyzer, Agilent Technologies, Waldbronn, Germany).

cDNA was reverse transcribed from 2.5 μl RNA using the TaqMan miRNA reverse transcription kit. qRT-PCR for the detection of hsa-miR-21 and miR-122 was carried out in 20 μl PCR reactions using the TaqMan MicroRNA assay with the StepOnePlus detection system (Applied Biosystems) at 50°C for 2 min then 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

**Statistical methods**

Expression levels of selected miRNAs detected by qRT-PCR were normalized to cel-miR-39 and presented as the fold-change (2^{−ΔΔCt}) above the control (Control-1): ΔΔCt = (CtmiRNA-Ctcel-miR-39) patient mean − (CtmiRNA-Ctcel-miR-39) control mean. Results for non-normally distributed continuous variables were summarized as medians (interquartile ranges) and were compared by the Mann-Whitney U test. Paired data were analyzed by non-parametric tests.
using the Wilcoxon signed-rank test for the comparison of paired data. Correlation coefficients (r) were calculated using the Spearman correlation.

**Results**

**Demographic data of AIH patients**

Table 1 shows demographic data of AIH patients. Among the 46 patients with type-1 AIH, 31 (67.4%) were positive for ANA (>1:40) and 32 (69.6%) for SMA (>1:40). Nine (19.6%) had liver cirrhosis at the time of diagnosis.

**Unique miRNA expression pattern in AIH**

We used the microarray system to determine those circulating miRNAs that were differentially expressed in AIH patients enrolled in Nagasaki Medical Center, Nagoya Medical Center and Ueda Medical Center. Of 2,555 miRNAs assayed, 811 were expressed at greater than background levels. S1 Fig shows the miRNAs that were expressed at higher levels in the sera from AIH patients compared with healthy subjects. A comparison between AIH patients and controls identified 11 miRNAs that were up-regulated by more than 1.7-fold (Table 2). Furthermore, comparing before and after successful glucocorticoid therapy identified 10 miRNAs that were down-regulated by up to 0.4-fold (S1 Fig and Table 3). Among these isolated miRNAs, miR-21 and miR-122 showed similar expression profiles, and were specifically up-regulated in untreated AIH patients and down-regulated in the remission phase after corticosteroid therapy.

**Table 1. Baseline Characteristics of 46 Japanese AIH Type 1 Patients.** AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphate; IgG, immunoglobulin G; ANA, anti-nuclear antibody; ASMA, anti-smooth muscle antibody; IQR, interquartile range; IAIHG, International Autoimmune Hepatitis Group.

| Characteristics         | n = 46 |
|-------------------------|--------|
| Female, n/total (%)     | 37/46  |
| Age, y, mean ± SD       | 59.6 ± 12.8 |
| Biochemistry            |        |
| AST, IU/L, median (IQR) | 290.5(97–724) |
| ALT, IU/L, median (IQR) | 405.5(115–842) |
| ALP, IU/L, median (IQR) | 437.5(347–514) |
| Total Bilirubin, mg/dl, median (IQR) | 1.3(0.9–3.3) |
| Albumin, g/dl, median (IQR) | 3.9(3.5–4.2) |
| IgG, mg/dl, median (IQR) | 1860.0(1584–2370) |
| Prothrombin time, %, median (IQR) | 81.3(72.3–89.0) |
| Platelets, 10^5/μl, median (IQR) | 18.0(14.4–21.2) |
| Serology                |        |
| ANA ≥:1:40, n/total (%) | 31/46(67.4) |
| ASMA ≥:1:40, n/total (%) | 32/46(69.6) |
| Histology               |        |
| Cirrhosis, n/total (%)  | 9/46(19.6) |
| IAIHG criteria          |        |
| Score, median (IQR)     | 17(15–18) |
Circulating levels of miR-21 and miR-122 in AIH and CHC patients

qRT-PCR was used to verify the data obtained from microarray analysis. Expression levels of miR-21 and miR-122 were normalized to spike-in cel-miR39 and were shown to be significantly elevated in AIH patients compared with both CHC patients and healthy subjects (S2 Fig).

### Table 2. Differentially expression miRNAs between control and AIH.

| no. | miR_name   | fold change |
|-----|------------|-------------|
| 1   | hsa-miR-122-5p | 7.34        |
| 2   | hsa-miR-1915-5p | 2.99        |
| 3   | hsa-miR-193b-3p | 2.83        |
| 4   | hsa-miR-1908-3p | 2.72        |
| 5   | hsa-miR-6073   | 2.63        |
| 6   | hsa-miR-99a-5p | 2.62        |
| 7   | hsa-miR-602    | 1.95        |
| 8   | hsa-miR-1199-5p | 1.87        |
| 9   | hsa-miR-1290   | 1.78        |
| 10  | hsa-miR-21-5p  | 1.77        |
| 11  | hsa-miR-4732-5p | 1.72        |

| no. | miR_name   | fold change |
|-----|------------|-------------|
| 1   | hsa-miR-223-3p | 0.14        |
| 2   | hsa-miR-575   | 0.16        |
| 3   | hsa-miR-451a  | 0.18        |
| 4   | hsa-miR-4638-5p | 0.25       |
| 5   | hsa-miR-4443  | 0.26        |
| 6   | hsa-miR-486-5p | 0.28        |
| 7   | hsa-miR-6765-3p | 0.29       |
| 8   | hsa-miR-6820-5p | 0.29       |
| 9   | hsa-miR-4648  | 0.30        |
| 10  | hsa-miR-6511a-5p | 0.32       |
| 11  | hsa-miR-6889-5p | 0.37       |
| 12  | hsa-miR-1207-5p | 0.38       |
| 13  | hsa-miR-7150  | 0.39        |
| 14  | hsa-miR-6877-5p | 0.40       |
| 15  | hsa-miR-4476  | 0.42        |
| 16  | hsa-miR-6763-5p | 0.43       |

doi:10.1371/journal.pone.0136908.t002

### Table 3. Differentially expression miRNAs between before and after corticosteroid therapy.

| no. | miR_name   | fold change |
|-----|------------|-------------|
| 1   | hsa-miR-23a-5p | 3.60        |
| 2   | hsa-miR-4450  | 3.15        |
| 3   | hsa-miR-4294  | 2.92        |
| 4   | hsa-miR-4478  | 2.87        |
| 5   | hsa-miR-4733-3p | 2.67        |
| 6   | hsa-miR-204-3p | 2.64        |
| 7   | hsa-miR-6076  | 2.60        |
| 8   | hsa-miR-4525  | 2.19        |
| 9   | hsa-miR-4665-5p | 2.07        |
| 10  | hsa-miR-4769-5p | 2.05        |
| 11  | hsa-miR-7641  | 1.92        |
| 12  | hsa-miR-4476  | 1.75        |
| 13  | hsa-miR-7150  | 1.75        |
| 14  | hsa-miR-6891-5p | 1.65        |
| 15  | hsa-miR-7109-5p | 1.59        |
| 16  | hsa-miR-6889-5p | 1.52        |

doi:10.1371/journal.pone.0136908.t003
Reversibility of the increased expressed miRNA corticosteroid therapy

Circulating levels of miR-21 and miR-122 were determined before and after corticosteroid therapy in paired serum samples from AIH patients. miR-21 and miR-122 were both shown to be up-regulated in untreated AIH patients, and down-regulated following glucocorticoid treatment of these same patients (S3 Fig).

Relationship between circulating miR-21 and miR-122 and liver function tests

To investigate the relationship between circulating miR-21 levels and standard liver function parameters, we examined correlations between circulating miR-21 or miR-122 and serum levels of AST or ALT (S4 Fig). A positive correlation was observed between serum miR-21 and miR-122 levels and AST (miR-21: r = 0.820, P<0.0001; miR-122: r = 0.628, P<0.0001) and ALT (miR-21: r = 0.761, P<0.0001; miR-122: r = 0.662, P<0.0001). However, the correlation rate was higher with respect to serum miR-21 compared with serum miR-122. We could not find a significant correlation between serum miR-21 or miR-122 levels and those of type IV collagen (S5 Fig).

Relationship between circulating miR-21 and miR-122, liver fibrosis and necroinflammation

As shown in S6 Fig, AIH patients with liver cirrhosis (LC) had significantly lower levels of circulating miR-21 and miR-122 compared with those without LC. Moreover, serum miR-21 and miR-122 levels were also shown to be reduced in AIH patients with an advanced fibrosis stage (S7A Fig). To evaluate whether serum miR-21 and miR-122 were correlated with hepatic necroinflammation, we evaluated these circulating miRNAs in AIH patients sub grouped according to the grading of necroinflammation. Liver necroinflammation grading correlated positively and significantly with circulating levels of miR-21, but not with miR-122 (S7B Fig).

Discussion

miRNA changes in the liver have been reported in diseases such as viral hepatitis and hepatocellular carcinoma (HCC) [16, 17]. However, little is known about their detection in the blood from AIH patients. The current study provides the first evidence that AIH is associated with altered circulating miRNA expression. We demonstrated that circulating has-miR-21 and miR-122 were significantly elevated in patients with AIH leading to a unique miRNA expression profile, but not in those with AIH combined with LC. We also detected strong correlations between serum miR-21 and miR-122 levels and ALT, a parameter of ongoing liver damage, and a negative correlation with liver fibrosis scores. The persistent liver damage responsible for perpetuating this process is characterised by the infiltration of immune cells into the liver and the death of hepatocytes. miRNAs are essential for the regulation of liver development, regeneration, and metabolic functions [18]. Hence, alternations in intrahepatic miRNA networks are associated with liver diseases, including hepatitis, steatosis, cirrhosis, and HCC. miR-122 is the most common miRNA with aberrant expression identified in liver disease, serving as a biomarker of liver injury in chronic hepatitis B or C, non-alcoholic fatty-liver disease, and drug-induced liver disease [19–22]. It is also an essential host factor for HCV infection and an antiviral target [23]. Circulating miR-122 levels were previously shown to be massively increased in response to hepatic injury and intrahepatic loss of miR-122 [24]. This loss was not significantly correlated with grades of inflammation in CHC infection, although it was significantly correlated with fibrosis in affected patients [25]. Our findings support
previous studies demonstrating liver-specific loss of miR-122 at late stages of fibrosis in CHC infection. However, our data showed that circulating miR-21 levels were significantly positively associated with grades of inflammation and negatively with fibrosis.

Haider et al. performed the global evaluation of miRNAs as biomarkers for non-neoplastic diseases [26]. They isolated six potential miRNA biomarkers of hepatic injury, of which only miR-122 was demonstrated to be liver-specific [26]. miR-122 significantly increased type I interferon (IFN) expression in hepatocytes, presumably through modulation of suppressor of cytokine signaling 1 expression [27]. These findings suggest that miR-122 may also contribute to autoimmunity in liver through the IFN-signaling pathway. It has also been demonstrated that miR-21 is induced after hepatectomy and contributes to liver regeneration by inducing the translation of cyclin D [28]. These data suggest that the higher miR-21 serum levels observed in AIH have similar functions to those seen after acute liver injury and following liver regeneration.

Mechanistically, it is possible for miR-21 to leak from damaged cells similar to ALT. These circulating levels are negatively regulated by hepatic fibrosis, as shown by the correlation between miR-21 and hepatic fibrosis. Our data are in line with these findings, indicating that serum miR-21 levels are related to liver damage activity rather than liver fibrosis in patients with CHC [29]. Thus, miR-21 and miR-122 may both originate from the inflamed liver in AIH, although miR-21, but not miR122, correlates with total bilirubin and the grading of liver inflammation. Therefore, serum levels of miR-21 and miR-122 reflect overlapping, but not identical, disease parameters in AIH patients. This might be related to the differential expression patterns of miR-21 and miR-122, with miR-122 being highly selective for the liver [30], whereas miR-21 shows strong expression in other cells such as lymphocytes [31]. Hepatic immune cell infiltrations or activation may contribute to the elevation of serum miR-21 levels in patients with AIH. miRNAs are crucial to many aspects of immunity, including T-cell immunity [32], so we speculate that circulating miR-21 mirrors the presence of immune-mediated hepatocyte injury in patients with AIH.

miR-21 plays a crucial role in T cells by sustaining the proliferation and repression of apoptosis. It has also been reported to target tumor suppressor genes such as Btf2, PDCD4, Pten, and sprout, which regulate cell death and proliferation [33]. miR21 directly down-regulates the expression of PDCD4, which encodes a protein that localizes to the nucleus and plays a role in pathogenic T cell apoptosis and cell proliferation [34, 35]. This leads to acquisition of an activated phenotype in normal T cells following miRNA-21 overexpression. miR-21 regulates aberrant T cell responses through control of PDCD4 expression in human systemic lupus erythematosus [36], suggesting that miR-21 induction enables T cells to elude apoptosis and enhance the secretion of pro-inflammatory cytokines such as interferon-γ and interleukin-17 by repressing PDCD4 expression [37].

More recently, it was demonstrated that the miR-21 pathway intrinsically controls Th17 differentiation. CD4+ T cells lacking miR-21 were shown to exhibit a specific Th17 cell defect affecting the transforming growth factor-β pathway during experimental autoimmune encephalomyelitis in vivo [37]. Given the ameliorating effect of ant-miR-21 observed in autoimmune model mice, the increased circulating miR-21 demonstrated in AIH patients in the present study could play a critical role in immune-mediated liver injury, which could be a contributing factor in the development of AIH. Recently, a report demonstrated that AP-1 is essential for miR-21 expression because mutations in AP-1 binding sites eliminated miR-21 promoter activity [38]. Moreover, glucocorticoid is thought to regulate miR-21 transcription through inhibiting the action of proinflammatory transcription factors such as AP-1 [39].

The present study has a number of limitations that should be considered when interpreting the results. First, we could not assess the relationship between the circulating levels of candidate
miRNAs and fluctuations of lupus disease activity with time. Second, because of the unknown impact of factors that regulate circulating miRNA levels, we were unable to normalize for the miRNA content using a reliable housekeeping miRNA. However, we supplemented the samples with recombinant cel-lin-4, which can be consistently detected by qRT-PCR, and detected no significant differences in raw Ct values of cel-lin-4 among the three groups (AIH, CHC, and control); thus, cel-miR39 was used to normalize the difference in the efficiency of RNA isolation. Additionally, our findings may not reflect other populations because we only focused on Japanese individuals. Hence, the sampling of other ethnic groups may result in a different circulating miRNA signature for AIH.

In conclusion, this is the first report to investigate the circulating miRNA profiles of AIH patients using microarray and quantitative real-time PCR analysis. We revealed that differential levels of serum miR-21 and miR-122 were associated with AIH, which may play important roles in disease pathogenesis. The mechanisms underlying the regulation of these aberrant circulating miRNAs remain to be investigated.

NHO-AIH study group

Kiyoshi Migita, Yuka Jiuchi, Atsumasa Komori, Hiroshi Yatsuhashi, Minoru Nakamura (NHO Nagasaki Medical Center), Hiroshi Kammitsukasa (NHO Tokyo National Hospital), Yoko Nakamura (NHO Sagamihara National Hospital), Hajime Ohta (NHO Kanazawa Medical Center), Masaki Shimada (NHO Nagoya Medical Center), Hironao Takahashi (NHO Higashi Nagoya National Hospital), Eiji Mita (Osaka National Hospital), Taizo Hijikata (NHO Osaka Minami Medical Center), Yabuuchi Iwao (NHO Minami Wakayama Medical Center), Haruhiro Yamashita (NHO Okayama Medical Center), Hiroshi Kouno (NHO Kure Medical Center), Noriaki Naeshiro (NHO Higashihiroshima Medical Center), Makoto Nakamuta (NHO Kyushu Medical Center), Keisuke Ario (NHO Ureshino Medical Center), Toyokichi Muro (NHO Oita Medical Center), Hironori Sakai (NHO Beppu Medical Center), Kazuhiro Sugi (NHO Kumamoto Medical Center), Hideo Nishimura (NHO Tokushima Medical Center), Kaname Yoshizawa (NHO Shinshu Ueda Medical Center), Takeaki Sato (NHO Kokura Medical Center), Atsushi Naganuma (NHO Takasaki General Medical Center), Tatsui Komatsu (NHO Yokohama Medical Center), Yukio Oohara (NHO Hokkaido Medical Center), Fujio Makita (NHO Nishigunma National Hospital), Minoru Tomizawa (NHO Shimoshizu National Hospital), Masahiro Kikuchi (NHO Tokyo Medical Center), Hiroshi Furukawa (University of Tsukuba Medical Molecular Genetic Epidemiology laboratory), Michio Yasunami (Institute of Tropical Medicine Nagasaki University).

Supporting Information

S1 Fig. Comparison of miRNA expressions in the sera from normal subjects and AIH patients by miRNA microarray. (A) Comparison of normalized signal intensities of various miRNAs in sera. X axis represents untreated AIH patients (n = 5) and Y axis represent healthy controls (n = 5). (B) Comparison of normalized signal intensities of various miRNAs in sera. X axis represents the sera from untreated (pretreatment) and Y axis represents the sera from after successful treatment (posttreatment) in the same AIH patients (n = 5). (GEO accession No: GSE71432)

S2 Fig. Quantitative real-time PCR analysis for miR-21 and miR-122 in patients with AIH, chronic hepatitis C (CHC) and healthy subjects. The vertical lines indicate the range, horizontal boundaries of the boxes represent the first and third quartile. Results were compared by
non-parametric Mann-Whitney test.

S3 Fig. Changes of serum miR-21 and miR-122 before and 4 weeks after the initiation of corticosteroid therapy. Thirty four AIH patients with paired serum samples (Before and 4 weeks after corticosteroid therapy) were subjected to qRT-PCR analysis for miR-122. The vertical lines indicate the range, horizontal boundaries of the boxes represent the first and third quartile. Paired samples from the same subjects were compared by Wilcoxon signed-rank test.

S4 Fig. Correlations between serum levels of miR-21 or miR-122 and AST (A) or ALT (B). Correlations between serum levels of miR-21 or miR-122 and serum AST levels were determined in patients with AIH. The correlation coefficient was determined by Pearson’s product statistic and the regression line is represented by the solid line.

S5 Fig. Correlations between serum levels of miR-21 or miR-122 and type IV collagen. Correlations between serum levels of miR-21 or miR-122 and serum type IV collagen levels were determined in patients with AIH. The correlation coefficient was determined by Pearson’s product statistic and the regression line is represented by the solid line.

S6 Fig. Serum levels of miR-21 or miR-122 in AIH patients with or without liver cirrhosis (LC). The vertical lines indicate the range, horizontal boundaries of the boxes represent the first and third quartile. Results were compared by non-parametric Mann-Whitney test.

S7 Fig. (A) Serum levels of miR-21 or miR-122(B) and relationship with stages of fibrosis. Correlations were assessed by Spearman’s rank correlation. Serum levels of miR-21 and miR-122 correlated inversely and significantly with the stage of fibrosis. (miR-21, \( r = -0.309, p = 0.013 \), miR-122, \( r = -0.324, p = 0.009 \)). (B) Serum levels of miR-21 or miR-122 and relationship with grades of necroinflammation. Correlations were assessed by Spearman’s rank correlation. Serum levels of miR-21 correlated positively and significantly with the grade of inflammation. (\( r = 0.3385, p = 0.001 \)).

Author Contributions
Conceived and designed the experiments: KM AK M. Nakamura MY HF H. Yatsuhashi. Performed the experiments: KM H. Kozuru YJ. Analyzed the data: KM YJ HF. Contributed reagents/materials/analysis tools: SA K. Yamasaki SN SH SB H. Kamitsukasa YN HO MS SH SB H. Yamashita H. Kouno M. Nakamuta KA TM HS KN K. Yoshizawa TS AN TK YO FM MT. Wrote the paper: KM AK HF.

References
1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215–33. doi: 10.1016/j.cell.2009.01.002 PMID: 19167326
2. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11: 145–56. doi: 10.1038/nrclinonc.2014.5 PMID: 24492836
3. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327: 198–201. doi: 10.1126/science.1176178 PMID: 19965718
4. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122—a key factor and therapeutic target in liver disease. J Hepatol. 2015; 62: 448–57. doi: 10.1016/j.jhep.2014.10.004 PMID: 25308172
5. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013; 10: 542–52. doi: 10.1038/nrgastro.2013.87 PMID: 23689081
6. Zeng L, Cui J, Wu H, Lu Q. The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity. 2014; 47: 419–29. doi: 10.3109/08916934.2012.692667 PMID: 24953646
7. Qin B, Huang F, Liang Y, Yang Z, Zhong R. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 2013; 28: 543–50. doi: 10.1111/j.1440-1746.2012.06686.x PMID: 23173724
8. Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013; 382: 1433–44. doi: 10.1016/S0140-6736(12)62163-1 PMID: 23768844
9. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol. 2000; 32: 181–97. PMID: 10728804
10. Csajka AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology. 2012; 14: 1431–43. doi: 10.1053/j.gastro.2010.04.053 PMID: 20451521
11. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology. 2012; 14: 1431–43. doi: 10.1053/j.gastro.2010.04.053 PMID: 20451521
12. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study). Liver Int. 2012; 32: 837–44. doi: 10.1111/j.1478-3231.2011.02734.x PMID: 22221966
13. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31: 929–38. PMID: 10580593
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19: 1513–20. PMID: 10851521
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105: 10513–8. doi: 10.1073/pnas.0804549105 PMID: 18663219
16. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122: 2884–97. doi: 10.1172/JCI63455 PMID: 22620290
17. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49: 1096–112. doi: 10.1002/hep.22749 PMID: 19173277
18. Chen Y, Verfaillie CM. MicroRNAs: the fine modulators of liver development and function. Liver Int. 2014; 34: 976–90. doi: 10.1111/liv.12496 PMID: 24517588
19. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2011; 106: 1663–9.
20. Waidmann O, Bihrer V, Plehl T, Farnik H, Berger A, Zeuzem S, et al. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat. 2012; 19: e58–65. doi: 10.1111/j.1365-2893.2011.01536.x PMID: 22239527
21. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011; 54: 1767–76. doi: 10.1002/hep.24538 PMID: 22045675
22. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013; 424: 99–103. doi: 10.1016/j.cca.2013.05.021 PMID: 23727030
23. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368: 1685–94. doi: 10.1056/NEJMoa1209026 PMID: 23534542
24. Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015; 35: 1172–84. doi: 10.1111/liv.12627 PMID: 25039534
25. Trebicka J, Anadol E, Elfmova N, Strack I, Roggendorf M, Viazov S, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 2013; 58: 234–9. doi: 10.1016/j.jhep.2012.10.015 PMID: 23085648
26. Haider BA, Baras AS, McCall MN, Hertel JA, Cornish TC, Halushka MK. A critical evaluation of microRNA biomarkers in non-neoplastic disease. PLoS One. 2014; 9: e89565. doi: 10.1371/journal.pone.0089565 PMID: 24586876

27. Li A, Song W, Qian J, Li Y, He J, Zhang Q, et al. MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1. Int J Biochem Cell Biol. 2013; 45: 858–65. doi: 10.1016/j.biocel.2013.01.008 PMID: 23348614

28. Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012; 122: 1097–108. doi: 10.1172/JCI46039 PMID: 22326957

29. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, Haupenthal J, et al. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One. 2011; 6: e26971. doi: 10.1371/journal.pone.0026971 PMID: 22066022

30. Girard M, Jacquemin E, Munnich A, Lyonne S, Henrion-Caude A. MiR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 2008; 48: 464–56. doi: 10.1016/j.jhep.2008.01.019 PMID: 18291553

31. Ruan Q, Wang P, Wang T, Qi J, Wei M, Wang S, et al. MicroRNA-21 regulates T-cell apoptosis by directly targeting the tumor suppressor gene Tipe2. Cell Death Dis. 2014; 5: e1095. doi: 10.1038/cddis.2014.47 PMID: 24577093

32. Xu WD, Pan HF, Li JH, Ye DQ. MicroRNA-21 with therapeutic potential in autoimmune diseases. Expert Opin Ther Targets. 2013; 17: 659–65. doi: 10.1517/14728222.2013.773311 PMID: 23506112

33. Sekar D, Hairul Islam VI, Thirugnanasambantham K, Saravanan S. Relevance of miR-21 in HIV and non-HIV-related lymphomas. Tumour Biol. 2014; 35: 8387–93. doi: 10.1007/s13277-014-2068-9 PMID: 24961346

34. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008; 283: 1026–33.

35. Allgayer H. Pdcd4, a colon cancer prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol. 2010; 73: 185–91. doi: 10.1016/j.critrevonc.2009.09.001 PMID: 19836969

36. Stagakis E, Bertasias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011; 70: 1496–506. doi: 10.1136/ard.2010.139857 PMID: 21602271

37. Ando Y, Yang GX, Kenny TP, Kawata K, Zhang W, Huang W, et al. Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. J Autoimmun. 2013; 41: 111–9. doi: 10.1016/j.jaut.2012.12.013 PMID: 23395552

38. Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev. 2013; 253: 167–84. doi: 10.1111/imr.12050 PMID: 23550646

39. González MV, Jiménez B, Berciano MT, González-Sancho JM, Caellés C, et al. Glucocorticoids antagonize AP-1 by inhibiting the activation/phosphorylation of JNK without affecting its subcellular distribution. J Cell Biol. 2000; 150: 1199–208. PMID: 10974006